Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 2915-2923

  Zhou, Jun ^a,b   Gong, Guanghui ^a,b   Tan, Hong ^a,b   Dai, Furong ^b   Zhu, Xin ^b   Chen, Yile ^c   Wang, Junpu ^a,b   Liu, Ying ^a,b   Chen, Puxiang ^b   Wu, Xiaoying ^a,b   Wen, Jifang ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c HUNAN CANCER HOSPITAL   (China)

Author keywords

Biomarker; MicroRNA; Non invasive; Ovarian serous adenocarcinoma; Urine

Indexed keywords

MICRORNA; MICRORNA 30A 5P; MICRORNA 6076; UNCLASSIFIED DRUG; MIRN30 MICRORNA, HUMAN; TUMOR MARKER;

ARTICLE; CANCER SURGERY; COLON CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; EXOSOME; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARIAN CANCER CELL LINE; OVARIAN SEROUS ADENOCARCINOMA; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; UPREGULATION; URINALYSIS; URINARY EXCRETION; AGED; BIOSYNTHESIS; CANCER STAGING; CYSTADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; URINE;

AGED; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 84928890115     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3937     Document Type: Article

References (30)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB and Herzog TJ: Fertility preservation in young women with epithelial ovarian cancer. Cancer 115: 4118-4126, 2009.
3. van Nagell JR Jr and Hoff JT: Transvaginal ultrasonography in ovarian cancer screening: Current perspectives. Int J Womens Health 6: 25-33, 2013.
4. Leung F, Diamandis EP and Kulasingam V: Ovarian cancer biomarkers: Current state and future implications from highthroughput technologies. Adv Clin Chem 66: 25-77, 2014.
5. Jacobs I and Bast RC Jr: The CA 125 tumour-associated antigen: A review of the literature. Hum Reprod 4: 1-12, 1989.
6. Cohen JG, White M, Cruz A and Farias-Eisner R: In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem 5: 286-300, 2014.
7. Berek JS and Bast RC Jr: Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 76 (Suppl 10): S2092-S2096, 1995.
8. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
9. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
10. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
11. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
12. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
13. Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY and Gleadle JM: Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 26: 3794-3802, 2011.
14. Lorenzen JM, Volkmann I, Fiedler J, Schmidt M, Scheffner I, Haller H, Gwinner W and Thum T: Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 11: 2221-2227, 2011.
15. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM and Sczakiel G: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28: 655-661, 2010.
16. Wang G, Tam LS, Li EK, Kwan BC, Chow KM, Luk CC, Li PK and Szeto CC: Serum and urinary cell-free miR-146a and miR-155 in patients with systemic lupus erythematosus. J Rheumatol 37: 2516-2522, 2010.
17. Luo Y, Wang C, Chen X, Zhong T, Cai X, Chen S, Shi Y, Hu J, Guan X, Xia Z, et al: Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. Clin Chem 59: 658-666, 2013.
18. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007.
19. Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13-21, 2008.
20. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM and Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 55-59, 2009.
21. Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, Qu A, Zhang X, Pan H, Yang Y, et al: Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer 136: 854-862, 2015.
22. Wang K, Jia Z, Zou J, Zhang A, Wang G, Hao J, Wang Y, Yang S and Pu P: Analysis of hsa-miR-30a-5p expression in human gliomas. Pathol Oncol Res 19: 405-411, 2013.
23. Vlassov AV, Magdaleno S, Setterquist R and Conrad R: Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 1820: 940-948, 2012.
24. Gu Y, Li M, Wang T, Liang Y, Zhong Z, Wang X, Zhou Q, Chen L, Lang Q, He Z, et al: Lactation-related microRNA expression profiles of porcine breast milk exosomes. PLoS One 7: e43691, 2012.
25. Keller S, Ridinger J, Rupp AK, Janssen JW and Altevogt P: Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med 9: 86, 2011.
26. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M and Ju J: Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2: 113-121, 2006.
27. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, et al: Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26: 7590-7595, 2007.
28. Li X, Zhang Y, Zhang Y, Ding J, Wu K and Fan D: Survival prediction of gastric cancer by a seven-microRNA signature. Gut 59: 579-585, 2010.
29. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 33: 732-739, 2012.
30. Jia Z, Wang K, Wang G, Zhang A and Pu P: MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth by targeting SEPT7. PLoS One 8: e55008, 2013.